Your browser is no longer supported. Please, upgrade your browser.
ONCS OncoSec Medical Incorporated daily Stock Chart
OncoSec Medical Incorporated
Index- P/E- EPS (ttm)-2.51 Insider Own1.00% Shs Outstand21.95M Perf Week41.12%
Market Cap64.30M Forward P/E- EPS next Y-1.53 Insider Trans-2.97% Shs Float9.21M Perf Month42.56%
Income-40.80M PEG- EPS next Q-0.46 Inst Own7.90% Short Float1.01% Perf Quarter87.84%
Sales- P/S- EPS this Y56.00% Inst Trans- Short Ratio0.38 Perf Half Y40.40%
Book/sh0.99 P/B2.81 EPS next Y36.50% ROA-153.60% Target Price- Perf Year26.36%
Cash/sh- P/C- EPS next 5Y- ROE-267.10% 52W Range1.04 - 2.97 Perf YTD53.59%
Dividend- P/FCF- EPS past 5Y19.40% ROI- 52W High-6.40% Beta2.12
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low167.56% ATR0.22
Employees37 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)74.05 Volatility11.98% 9.25%
OptionableNo Debt/Eq0.05 EPS Q/Q56.40% Profit Margin- Rel Volume11.98 Prev Close1.95
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume242.03K Price2.78
Recom1.70 SMA2036.24% SMA5035.50% SMA20046.18% Volume2,898,507 Change42.56%
Nov-07-18Downgrade H.C. Wainwright Buy → Neutral $4 → $1
Feb-09-18Initiated Piper Jaffray Overweight $4
Jul-21-16Resumed Rodman & Renshaw Buy $6
Jul-21-16Reiterated Maxim Group Buy $17 → $5
Jun-16-15Reiterated Maxim Group Buy $60 → $17
Jul-13-20 09:00AM  
Jul-09-20 09:00AM  
Jun-24-20 09:00AM  
Jun-22-20 09:05AM  
Jun-09-20 09:00AM  
Jun-04-20 09:00AM  
Jun-03-20 09:00AM  
May-27-20 09:00AM  
May-21-20 09:00AM  
May-14-20 09:00AM  
May-13-20 09:18AM  
May-06-20 09:00AM  
Apr-21-20 09:00AM  
Apr-20-20 09:00AM  
Apr-06-20 09:00AM  
Mar-20-20 09:00AM  
Mar-17-20 08:30AM  
Mar-11-20 08:30AM  
Mar-09-20 08:30AM  
Feb-11-20 08:30AM  
Feb-10-20 08:30AM  
Feb-07-20 10:53AM  
Feb-04-20 08:30AM  
Feb-03-20 09:48AM  
Jan-31-20 08:30AM  
Jan-28-20 08:30AM  
Jan-27-20 11:00AM  
Jan-21-20 04:30PM  
Jan-17-20 09:30AM  
Jan-16-20 08:30AM  
Jan-15-20 12:38PM  
Jan-14-20 08:30AM  
Jan-07-20 04:30PM  
Jan-06-20 08:30AM  
Dec-30-19 08:45AM  
Dec-26-19 08:43AM  
Dec-20-19 03:16PM  
Dec-18-19 08:32AM  
Dec-17-19 06:30PM  
Dec-16-19 08:30AM  
Dec-13-19 08:30AM  
Dec-12-19 08:30AM  
Dec-09-19 08:30AM  
Dec-06-19 12:30PM  
Dec-05-19 09:46AM  
Dec-04-19 09:00AM  
Dec-02-19 08:00AM  
Nov-27-19 08:30AM  
Nov-26-19 08:30AM  
Nov-20-19 09:15AM  
Nov-15-19 08:56AM  
Nov-12-19 08:30AM  
Nov-05-19 08:30AM  
Oct-30-19 12:44PM  
Oct-21-19 09:00AM  
Oct-15-19 08:30AM  
Oct-10-19 03:09PM  
Sep-26-19 08:00AM  
Sep-20-19 08:00AM  
Sep-06-19 08:00AM  
Jul-29-19 08:40AM  
Jul-16-19 08:30AM  
Jun-27-19 08:30AM  
Jun-17-19 08:30AM  
Jun-13-19 08:30AM  
Jun-07-19 10:25AM  
Jun-06-19 06:42AM  
May-29-19 08:30AM  
May-28-19 08:30AM  
May-24-19 01:46PM  
May-23-19 08:30AM  
May-22-19 09:44AM  
May-21-19 04:01PM  
May-20-19 12:45PM  
Apr-29-19 08:00AM  
Apr-28-19 09:59AM  
Apr-24-19 08:00AM  
Apr-23-19 08:00AM  
Apr-17-19 08:00AM  
Apr-10-19 08:00AM  
Apr-09-19 08:00AM  
Apr-08-19 08:00AM  
Apr-02-19 08:00AM  
Apr-01-19 08:00AM  
Mar-27-19 08:16AM  
Mar-13-19 08:30AM  
Feb-28-19 08:00AM  
Feb-08-19 08:00AM  
OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the Phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company is developing new DNA-encoded therapeutic candidates and tumor indications. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a collaborative research agreement with Duke University School of Medicine to evaluate TAVOPLUS; a collaboration with Dana-Farber Cancer Institute and the Marasco Laboratory to develop CAR T-cell therapies for triple-negative breast cancer and ovarian cancer; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and TAVO; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Connor Daniel J.CEO and PresidentApr 30Sale1.793,0755,50462,986May 04 06:07 PM
O'Connor Daniel J.CEO and PresidentJan 31Sale1.962,6545,20266,061Feb 03 08:00 PM
Bonstein SaraCFO/COOJan 16Sale2.081,3512,81041,389Jan 21 04:15 PM
O'Connor Daniel J.CEO and PresidentOct 31Sale2.162,1284,59668,715Nov 01 08:00 PM
Bonstein SaraCFO/COOOct 16Sale2.011,1112,23342,740Oct 18 08:00 PM
Alpha Holdings, Inc.DirectorJul 17Buy2.5730,00077,1001,611,000Jul 19 09:55 PM
Alpha Holdings, Inc.DirectorJul 16Buy2.3460,000140,4001,581,000Jul 17 09:55 PM
Alpha Holdings, Inc.DirectorJul 15Buy2.2230,00066,6001,521,000Jul 17 09:55 PM